natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of any of claims 1 to 13 for use in the prophylaxis or treatment of diabetes. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se on upotrebljava za profilaksu ili liječenje dijabetesa.
The pharmaceutical composition according to any one of the preceding claims characterised in that it is used for the treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, and an autoimmune disease. 
Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da se koristi za liječenje medicinskog stanja koje je odabrano od kronične limfocitne leukemije, akutne limfocitne leukemije, kronične mijeloične leukemije akutne mijeloične leukemije, Hodgkinove bolesti, non-Hodgkinovog limfoma, multiplog mijeloma, raka dojke, raka jajnika, karcinoma pluća malih stanica, karcinoma pluća ne-malih stanica, te autoimune bolesti.
The pharmaceutical composition according to any one of the preceding claims, characterised in that it is to be administered in combination with at least one further active agent, wherein said further active agent is given prior, concurrently, or subsequently to the administration of the pharmaceutical composition and is selected from the group consisting of an antibody specific for CD20, an anthracyclin derivative, a vinca alkaloid or a platin derivative. 
Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da se daje u kombinaciji sa barem jednim dodatnim aktivnim sredstvom, pri čemu se navedeno dodatno aktivno sredstvo daje prije, istovremeno, ili poslije davanja farmaceutskog pripravka, te je odabrano iz skupine koja sadrži specifično antitijelo za CD20, derivat antraciklina, vinka alkaloid ili derivat platine.
The pharmaceutical composition according to claim 10, characterised in that the antibody specific for CD20 is rituximab; the anthracyclin derivative is doxorubicin or daunorubicin; the vinca alkaloid is vincristine and the platin derivative is cisplatin or carboplatin. 
Farmaceutski pripravak prema zahtjevu 10, naznačen time da specifično antitijelo za CD20 je rituksimab; derivat antraciklina je doksorubicin ili daunorubicin; vinka alkaloid je vinkristin i derivat platine je cisplatin ili karboplatin.
Mechanism (1) according to the claim 1 characterized in that that a sensor for measuring the launching speed of the ball (11) is provided and which has a built in bus (19), whereby in use the measured speed which is below a foreseen minimum speed causes nullification of the game. 
Mehanizam (1) prema zahtjevu 1 naznačen time da je predviđen jedan senzor za mjerenje brzine izbacivanja kuglice (11) koji ima ugrađenu sabirnicu (19), tako da prilikom uporabe izmjerena brzina koja je manja od predviđene minimalne brzine, prouzročuje poništavanje igre.
Mechanism (1) according to the claim 1, characterized in that a sensor for measuring the launching speed of the ball (11) is provided and which has a built in bus (19), whereby in use the measured speed at an individual game is considered in a computerized correction of the speed of the rotating part of the roulette wheel. 
Mehanizam (1) prema zahtjevu 1, naznačen time da je predviđen jedan senzor za mjerenje brzine izbacivanja kuglice (11) koji ima ugrađenu sabirnicu (19), tako da se prilikom uporabe izmjerena brzina u pojedinoj igri uzima u obzir u obliku kompjuterski korigirane brzine rotirajućeg dijela kola ruleta.
A method for modulating opioid receptor function in a cell, comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a compound according to any one of claims 1 to 9, wherein the compound preferably modulates µ-opioid receptor function, or acts as an agonist at the µ-opioid receptor. 
In vitro postupak za modulaciju funkcije opioidnog receptora u stanici, koji se sastoji od kontakta stanice koja može eksprimirati opioidni receptor sa učinkovitom količinom spoja prema bilo kojem zahtjevu od 1 do 23, naznačen time da spoj poželjno (a) modulira funkciju µ-opioidnog receptora, ili (b) djeluje kao agonist na µ-opioidni receptor.
allowing the antibody or functional fragment thereof to bind to amyloid protein to form an immunological complex; 
omogućavanja da se protutijelo veže na sve amiloidne proteine u uzorku kako bi tvorilo imunološki kompleks;
allowing the antibody or functional fragment thereof to bind to amyloid protein to form an immunological complex; 
omogućavanju da se protutijelo veže na amiloidni protein kako bi tvorilo imunološki kompleks;
allowing the antibody or functional fragment thereof to bind to amyloid protein to form an immunological complex; 
omogućavanja da se protutijelo veže na amiloidni protein kako bi tvorilo imunološki kompleks;
A method of suppressing expression of a gene encoding a protein, comprising introducing the single-chain circular RNA according to any one of claims 1 to 3 to non-human animals, plants or cells thereof, and impairing a target RNA by the single-chain circular RNA to inhibit translation of the target RNA into the protein in a sustained manner. 
Metoda za suzbijanje ekspresije gena koji kodira protein, naznačena time, da uključuje uvođenje in vitro jednolančanu kružnu RNK prema bilo kojem od zahtjeva 1 do 3, u stanice životinje ili biljke ne-ljudskog podrijetla, te ometanje ciljane RNK s jednolančanom kružnom RNK čime se inhibira prevođenje ciljne RNK u protein na održiv način.
A pharmaceutical composition comprising human placental stem cells for use in a method of treating graft-versus-host disease in a human, wherein said placental stem cells detectably suppress T cell proliferation stimulated by Epstein-Barr virus antigen-presenting B cells, wherein said placental stem cells are not trophoblasts, and wherein at least 80% of said placental stem cells express CD200 and HLA-G; 
Matične stanice iz posteljice namijenjene upotrebi u postupku suprimiranja imunosnog odgovora, naznačene time što navedene matične stanice iz posteljice uočljivo suprimiraju proliferiranje T-stanica stimulirano od strane B-stanica koje predočavaju antigene iz Epstein-Barrovog virusa, gdje navedene matične stanice iz posteljice nisu trofoblasti, te gdje najmanje 80% od navedenih matičnih stanica iz posteljice eksprimira CD200 i HLA-G;
The pharmaceutical composition of any one of claims 1-3, wherein said placental stem cells suppress CD4+ or CD8+ T cell proliferation by at least 50%, by at least 75%, by at least 90%, or by at least 95% compared to an amount of T cell proliferation in the absence of said placental stem cells. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što navedene matične stanice iz posteljice suprimiraju CD4+ ili CD8+ proliferiranje T-stanica najmanje 50%, najmanje 75%, najmanje 90% ili najmanje 95% u usporedbi s razinom proliferiranja T-stanica u odsutnosti navedenih matičnih stanica iz posteljice.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 25, te farmaceutski prihvatljiv nosač ili razrjeđivač.
liquid tumour cancer; or hematological cancer; or colon cancer, gastric cancer, breast cancer, lung cancer, acute myeloid leukemia, thyroid cancer, ocular cancer, prostate cancer, ocular melanoma cancer, ovarian cancer, renal cancer, skin cancer, or squamous cell carcinoma. 
proliferativno stanje; ili rak; ili rak čvrstog tumora; ili rak tekućeg tumora; ili hematološki rak; ili rak debelog crijeva, gastrički rak, rak dojke, rak pluća, akutna mijeloidna leukemija, tiroidni rak, očni rak, rak prostate, rak očnog melanoma, rak jajnika, rak bubrega, rak kože ili karcinom rožnatih stanica.
The isolation system of claim 2, wherein said isolating washer (26) is comprised of suitable metal core coated with a dielectric material. 
Izolacijski sustav prema zahtjevu 2, naznačen time, da se spomenuti izolacijski zaporni prsten (26) sastoji od prikladne metalne jezgre obložene dielektričnim materijalom.
The isolation system of claim 1, wherein said isolating sleeve (22) further comprises a sleeve made of one of glass reinforced polymer material, epoxy material, phenolic material, and meta-aramid material. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti izolacijski naglavak (22) nadalje obuhvaća naglavak načinjen od jednog od sljedećih materijala: polimerni materijal ojačan staklom, epoksi materijal, fenolni materijal i meta-aramidni materijal.
The isolation system of claim 1, wherein said metal fastener (18) further comprises a metal shaft threaded to receive a nut on at least one of said opposing ends. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti metalni pričvršćivač (18) nadalje obuhvaća metalni vijak s navojem za prihvat matice na najmanje jednom od spomenutih suprotnih krajeva.
The isolation system of claim 1, wherein said primary seal element (50) comprises a polytetrafluoroethylene (PTFE) spring energized lip seal or an elastomeric o-ring. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti primarni zaptivni element (50) obuhvaća rubnu brtvu od politetrafluoroetilena (PTFE) nategnutu oprugom ili elastomernim O-prstenom.
The isolation system of claim 1, wherein said annular metal seal element (52) has a coating of dielectric material. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti prstenasti metalni zaptivni element (52) ima oblogu od dielektričnog materijala.
The isolation system of claim 1, wherein said compression limiter (54) is coated with a dielectric material. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da je spomenuti tlačni graničnik (54) obložen s dielektričnim materijalom.
and R2, are both -OR8, or R1 and R2, together with the carbon atom to which they are attached, form dioxacycloalkyl; 
i R2 su oba -OR8, ili R1 i R2, zajedno s atomom ugljika na kojeg su vezani, tvore dioksacikloalkil;
and R14 are selected as follows: 
i R14 se bira kao što slijedi:
and R20, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy; 
i R20, zajedno s atomom dušika na kojeg su vezani, tvore heterociklil ili heteroaril koji je izborno supstituiran s 1 do 2 skupine, od kojh se svaku neovisno bira između halogena, alkila, halogenalkila, hidroksila i alkoksi;
Ry and Rz are selected as follows: 
Ry i Rz se bira kao što slijedi:
Rw is independently hydrogen or alkyl; 
Rw je neovisno vodik ili alkil;
The compound for use of claim 12, wherein the disease is cancer, myeloproliferative disorder, inflammation or autoimmune disease. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je bolest rak, mijeloproliferativni poremećaj, upala ili autoimuna bolest.
The process according to any one of claims 1 to 7, wherein the carboxylic groups of the at least one modified polysaccharide are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more polyvalent cations, wherein the polyvalent cations preferably are selected from Sr2+, Ca2+, or Mg2+, and most preferably from Ca2+ added in form of Ca(OH)2 in suspension and/or solution. 
Postupak prema bilo kojem od zahtjeva 1 do 7, gdje su karboksilne skupine barem jednog modificiranog polisaharida barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, pri čemu su polivalentni kationi poželjno izabrani od Sr2+, Ca2+, ili Mg2+, i najpoželjnije od Ca2+ dodanog u obliku Ca(OH)2 u suspenziji i/ili otopini.
The process according to any one of claims 1 to 7, wherein the carboxylic groups of the at least one modified polysaccharide are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt such as Na2HP04, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 7, gdje su karboksilne skupine barem jednog modificiranog polisaharida barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3PO4, ili kiselo reaktivne soli kao što je Na2HPO4, poželjno CaHPO4.
The process according to any one of claims 1 to 7, wherein the carboxylic groups of the at least one modified polysaccharide are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more monovalent cations, wherein the monovalent cations preferably are selected from Li+, Na+, or K+. 
Postupak prema bilo kojem od zahtjeva 1 do 7, gdje su karboksilne skupine barem jednog modificiranog polisaharida barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više monovalentnih kationa, pri čemu su monovalentni kationi poželjno izabrani od Li+, Na+, ili K+.
Ulipristal acetate (17a-acetoxy-11β-[4- N, N -dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione) or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids. 
Ulipristal acetat (17a-acetoksi-11β-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered by oral route. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje oralnim putem.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered in a form of a tablet. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku tablete.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to any one of claims 1-3 wherein it is to be administered with a daily dosage of 5 to 15 mg . 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema bilo kojem od zahtjeva 1-3 pri čemu se primjenjuje u dnevnoj dozi od 5 do 15 mg.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 4 wherein it is to be administered with a daily dosage of 10 mg. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 4 pri čemu se primjenjuje u dnevnoj dozi od 10 mg.
Ulipristal acetate for use in reducing or stopping bleedings in a patient suffering from uterine fibroids. 
Ulipristal acetat za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered in form of an oral dosage during a period of about 2 to about 4 months. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 7 which is repeated once a year. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 7 u ponavljanju od jednom godišnje.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein ulipristal acetate or the said metabolite further acts as a contraceptive. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu ulipristal acetat ili metabolit dalje djeluje kao kontraceptiv.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein said patient suffers or is susceptible to suffer from anemia. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu ta bolesnica boluje od ili je podložna bolovanju od anemije.
Ulipristal acetate (17a-acetoxy-11β-[4- N, N -dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione) or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 for a further use in preventing or treating anemia in said patient. 
Ulipristal acetat (17a-acetoksi-11β-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice.
The composition for use of claim 1, further comprising at least one additional compound selected from the group consisting of Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Aminocaproic acid, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide, or pharmaceutically acceptable salts thereof. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difilin, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
The composition for use of claim 1 or 2, comprising at least: 
Smjesa za uporabu prema zahtjevu 1 ili 2, sadrži barem:
The composition for use of claim 1, comprising at least: 
Smjesa za uporabu prema zahtjevu 1, sadrži barem:
Baclofen, Acamprosate and Memantine, or pharmaceutically acceptable salts thereof. 
baklofen, akamprozat i memantin, ili njihove farmaceutski prihvatljive soli.
The composition for use of claim 1, comprising Baclofen and Acamprosate as the only active agents. 
Smjesa za uporabu prema zahtjevu 1, sadrži baklofen i akamprozat kao jedine djelatne tvari.
The composition for use of anyone of claims 1 to 6, wherein the compounds are formulated or administered together, separately or sequentially. 
Smjesa za uporabu prema bilo kojem od zahtjeva 1 do 6, gdje su spojevi oblikovani ili primijenjeni zajedno, odvojeno ili uzastopce.
Baclofen, or a pharmaceutically acceptable salt thereof, in combination with at least Acamprosate, or a pharmaceutically acceptable salt thereof, for use in improving cognitive symptoms in a subject suffering from, predisposed to, or suspected to suffer from Alzheimer's disease. 
Baklofen, ili njegova farmaceutski prihvatljiva sol, u kombinaciji s barem akamprozatom, ili njegovom farmaceutski prihvatljivom soli, za uporabu u poboljšanju kognitivnih simptoma u subjekta koji boluje od, ima predispoziciju ili se sumnja da boluje od Alzheimerove bolesti.
The composition of claim 1, further comprising at least one compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplererone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide, or a pharmaceutically acceptable salt thereof 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difilin, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
A process for obtaining a pharmaceutical composition containing glatiramer acetate, which comprises 
Postupak za dobivanje farmaceutskog sastava koji sadrži smjesu glatiramer acetata i u čemu smjesa ima željenu prosječnu molekularnu težinu, naznačen time, da obuhvaća:
A process for preparing a pharmaceutical composition containing glatiramer acetate, wherein the glatiramer acetate has a predetermined percentage of brominated tyrosine acceptable for inclusion in a pharmaceutical composition, which comprises obtaining a batch of glatiramer acetate; 
Postupak za pripremu farmaceutskog sastava koji sadrži smjesu glatiramer acetata, naznačen time, da smjesa ima predodređeni postotak bromiranog tirozina, koji je postotak prihvatljiv za uključivanje u farmaceutski sastav, i koji postupak obuhvaća dobivanje šarže glatiramer acetata;
A modular system for providing bicycles at a given location according to a desired configuration, the modular system comprising: 
Modularni sustav za ponudu bicikala na zadanoj lokaciji prema željenoj konfiguraciji, modularni sustav obuhvaća: